CD3

Venture Capital Flemish Brabant, Belgium ·Founded 2006

Overview

CD3 is a venture capital firm and drug discovery center based in Leuven, Belgium, dedicated to transforming groundbreaking biomedical research into new medicines. By collaborating with academic research groups and biotech companies, CD3 bridges the gap between innovative science and the pharmaceutical industry, creating value for all stakeholders involved. Their mission is to discover new medicines that address some of the most serious medical needs of our time. The firm focuses on investing in drug discovery projects, spin-off companies, and biotech firms, providing them with experienced drug discovery teams and state-of-the-art infrastructure. CD3 has a strong track record, having initiated over 35 drug discovery projects and established more than 15 partnerships with pharmaceutical or biotech companies. Their portfolio includes investments in various therapeutic areas, such as infectious diseases, cancer, and respiratory illnesses. In October 2023, CD3 successfully closed its fourth fund, raising €70.5 million, bringing the total capital managed by the firm to €154.5 million. This funding, provided by KU Leuven Research & Development (LRD), the European Investment Fund (EIF), and the Gemma Frisius Fund (GFF), supports the firm's ongoing efforts to advance biomedical discoveries from academic research groups and biotech companies into new medicines that improve people's lives worldwide.

Investment Focus

  • Innovative biomedical research
  • Strong scientific foundation
  • Potential for commercialization
  • Experienced management team
  • Clear regulatory pathway
  • Scalable business model
  • Addressing significant medical needs
  • Competitive advantage
  • Sustainable business practices
  • Alignment with CD3's therapeutic focus areas

Portfolio Companies

Enedra TherapeuticsYap/TAZ-TEAD InhibitorsRSV Antivirals

Get the full list of 54,000+ investors

CD3 and every other firm and angel in the database — as one spreadsheet you keep.

$19one-time payment · no subscription
  • All 54,000+ investors — VC firms, private equity, family offices and angels
  • The key person to contact at each one, with their job title
  • Their work email address
  • Their phone number
  • Their LinkedIn profile
  • Delivered as a single .xlsx file — download it as many times as you like
Get the full list — $19 → One payment. No seats, no credits, no expiry. Already bought it? Sign in to download it again — no second payment.

Every profile on this site is one row of the file, with the contact details masked — browse a few before you buy.

Frequently asked questions about CD3

What sectors does CD3 invest in?

CD3 invests in Healthcare, Life Sciences, Pharmaceuticals, Medical Devices, Diagnostics and Biotechnology, and is based in Flemish Brabant, Belgium. CD3 is listed as a venture capital in the ConnectSafely investor database.

What stage does CD3 invest at?

CD3 backs companies at Seed, Early Stage, Series A, Series B, Growth and Late Stage, writing cheques of 1M - 50M.

Which regions does CD3 invest in?

CD3 invests across United States, United Kingdom, Germany, France, Italy and Denmark.

What companies has CD3 invested in?

CD3's portfolio includes Enedra Therapeutics, Yap/TAZ-TEAD Inhibitors and RSV Antivirals.

Last updated · Source: ConnectSafely investor database